The Senate Health, Education, Labor and Pensions Committee voted 16-7 in favor of an amendment that would provide 12 years of intellectual property protection for biotech drugs to shield them from competition with follow-on biologics. The amendment is part of the health care reform bill, which could be approved by the committee as early as today.

Related Summaries